Trial Profile
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2019
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms Bydureon
- Sponsors AstraZeneca
- 19 Dec 2016 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Planned number of patients changed from 110 to 115.
- 09 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017.